Figure 4

T-cell engager efficacy is driven by several factors leading to highly superior efficacy of trispecific antibodies at lower doses but comparable performance as dose increases. Comparison of trispecific simulated over three days to comparable bispecific with no CD28 binding. MM cell receptor occupancy and “effective” receptor occupancy for bispecific and trispecific, respectively (A, B). (C) Killing was predicted across the in vitro population for varying doses of the bispecific compared to trispecific. MM cell distribution and T-cell distribution are shown at final timepoint (D, E) for bispecific and trispecific, respectively. (F) Schematic of the prevalent forces driving dose–response curve. Blue line and boxes describe trispecific dose–response and levels of ineffective synapses, receptor occupancy, total T-cells, and active T-cells. Green line and boxes show bispecific simulation.